Literature DB >> 18852573

The new approach: psychosocial functioning as a necessary outcome criterion for therapeutic success in schizophrenia.

Georg Juckel1, Pier Luigi Morosini.   

Abstract

PURPOSE OF REVIEW: Although in the past most attention was paid to psychopathology, these days outcome parameters such as cognitive and occupational performance, emotional stability, quality of life and psychosocial functioning are being recognized as important determinants of treatment success. Instead of only reducing the symptoms, therapy with antipsychotics must attain higher goals such as remission and recovery today. RECENT
FINDINGS: The Psychosocial Performance Scale offers a validated, reliable and operational tool to assess the psychosocial functioning of patients during the course of treatment as well as in the acute state. The Mini-ICF-P might be a similar instrument for measuring psychosocial functioning.
SUMMARY: In the future, medication and non-medication treatment strategies will also be judged by the ability to improve the psychosocial functioning of patients with schizophrenia, as measured by the Personal and Social Performance scale and the Mini-ICF-P.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18852573     DOI: 10.1097/YCO.0b013e328314e144

Source DB:  PubMed          Journal:  Curr Opin Psychiatry        ISSN: 0951-7367            Impact factor:   4.741


  25 in total

1.  Social Disconnection in Schizophrenia and the General Community.

Authors:  Michael F Green; William P Horan; Junghee Lee; Amanda McCleery; L Felice Reddy; Jonathan K Wynn
Journal:  Schizophr Bull       Date:  2018-02-15       Impact factor: 9.306

2.  Is it the symptom or the relation to it? Investigating potential mediators of change in acceptance and commitment therapy for psychosis.

Authors:  Brandon A Gaudiano; James D Herbert; Steven C Hayes
Journal:  Behav Ther       Date:  2010-06-09

3.  Is personal and social functioning associated with subjective quality of life in schizophrenia patients living in the community?

Authors:  Sofia Brissos; Vicent Balanzá-Martinez; Vasco Videira Dias; Ana Isabel Carita; Maria Luisa Figueira
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2011-03-08       Impact factor: 5.270

4.  Predicting hospital admission and discharge with symptom or function scores in patients with schizophrenia: pooled analysis of a clinical trial extension.

Authors:  Chris M Kozma; Riad G Dirani; Carla M Canuso; Lian Mao
Journal:  Ann Gen Psychiatry       Date:  2010-06-02       Impact factor: 3.455

Review 5.  The impact of newer atypical antipsychotics on patient-reported outcomes in schizophrenia.

Authors:  A George Awad; Lakshmi N P Voruganti
Journal:  CNS Drugs       Date:  2013-08       Impact factor: 5.749

6.  Social cognition and metacognition in obsessive-compulsive disorder: an explorative pilot study.

Authors:  Paraskevi Mavrogiorgou; Mareike Bethge; Stefanie Luksnat; Fabio Nalato; Georg Juckel; Martin Brüne
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2016-01-25       Impact factor: 5.270

7.  Reward processing in certain versus uncertain contexts in schizophrenia: An event-related potential (ERP) study.

Authors:  Peter E Clayson; Jonathan K Wynn; Zachary P Infantolino; Greg Hajcak; Michael F Green; William P Horan
Journal:  J Abnorm Psychol       Date:  2019-11

8.  [Psychiatric comorbidities in hidradenitis suppurativa/acne inversa].

Authors:  Paraskevi Mavrogiorgou; Georg Juckel; Andreas Reimelt; Schapoor Hessam; Lisa Scholl; Jessica Lisa Frajkur; Eggert Stockfleth; Falk G Bechara
Journal:  Hautarzt       Date:  2021-01-04       Impact factor: 0.751

9.  Empirically Based Psychosocial Therapies for Schizophrenia: The Disconnection between Science and Practice.

Authors:  Glenn D Shean
Journal:  Schizophr Res Treatment       Date:  2013-04-23

Review 10.  Disability and schizophrenia: a systematic review of experienced psychosocial difficulties.

Authors:  Piotr Świtaj; Marta Anczewska; Anna Chrostek; Carla Sabariego; Alarcos Cieza; Jerome Bickenbach; Somnath Chatterji
Journal:  BMC Psychiatry       Date:  2012-11-09       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.